NEW YORK, Feb. 7 - Mary Callan, former director of business development at Exelixis, has been appointed vice president of business development at Morphotek, the company announced Feb. 5. Morphotek, a privately-owned
Callan has also served as head of business development at Large Scale Biology Corporation, and has worked in research at BASF.
George Milne, former executive vice president of global R&D at Pfizer, was appointed to Athersys' board of directors, the company announced Feb. 4. Athersys, of
Milne recently retired from Pfizer after working at the company in research and management positions since 1970. He replaces George LeMaitre, head of
Agilent Technologies created a new scientific advisory board, the company said Feb., 4, and appointed to it:
Paul Herring, director of corporate research at Novartis International. Herring is also a professor of drug discovery sciences at the
Anthony Martin, president and CEO of Molecular Probes. Martin has worked for over 25 years in biotech, most recently serving as president of Invitrogen's molecular biology division.
Mark Skolnick, founder of Myriad Genetics. Skolnick directed the group that cloned several disease-related mutation groups, including the BRCA1 gene for susceptibility to breast cancer, the MMAC1 tumor suppressor gene, the prostate cancer gene HPC2; and also did significant work on p16 and BRCA2.
Wendell Wierenga, CEO of protein structure drug discovery company Syrrx. Wierenga was earlier a senior VP of Parke-Davis/Warner Lambert, which has since been acquired by Pfizer.
The board, which met for the first time earlier this week, is expected to meet two or three times each year.
Scott Kahn has been promoted to chief science officer at Pharmacopeia subsidiary Accelrys, the company said Feb. 3. Khan previously served as general manager and senior vice president of the company's life sciences division.
Before joining Accelrys, Khan was an assistant professor of chemistry at the
Louise Henry has been named vice president, quality, and Mark Enyedy has been named vice president of business development, for Vertex Pharmaceuticals, the company said Feb. 3.
Henry previously served as director of quality operations and quality global product development at Eli Lilly. Enyedy joins Vertex from Genzyme, where he was vice president of business development.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail Marian Jones at